The results obtained from 95 patients who underwent breast cancer during the biennium 1983-1985, by type of intervention performed analyzes. In most patients they have undergone a modified PATEY, following the HALSTED number and a simple mastectomy, more cleaning axillary The lymph nodes was classified into 3 levels or stages. Our approach is to keep the pectoralis major long as it is not affected by the tumor and removal of the pectoralis minor, for better subclavian surgical time.

The results obtained from 95 patients who underwent breast cancer during the biennium 1983-1985, by type of intervention performed analyzes. In most patients they have undergone a modified PATEY, following the HALSTED number and a simple mastectomy, more cleaning axillary The lymph nodes was classified into 3 levels or stages. Our approach is to keep the pectoralis major long as it is not affected by the tumor and removal of the pectoralis minor, for better subclavian surgical time.

Purpose: Predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC) have been recently proposed using samples from phase III clinical trials, including non-basal phenotype and biomarkers related to angiogenesis, stroma, and capecitabine activation genes. We aimed to validate these findings on the larger phase III GEICAM/CIBOMA clinical trial. Experimental Design: Tumor tissues from patients with TNBC randomized to standard (neo)adjuvant chemotherapy followed by capecitabine versus observation were analyzed using a 164-gene NanoString custom nCounter codeset measuring mRNA expression. A prespecified statistical plan sought to verify the predictive capacity of PAM50 non-basal molecular subtype and tested the hypotheses that breast tumors with increased expression of (meta) genes for cytotoxic cells, mast cells, endothelial cells, PDL2, and 38 individual genes be...